Home Featured Page 158

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psilocybin in the Treatment of Alcohol Use Disorder

Clearmind Announces Notice of Proposed Stock Consolidation

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES...

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Psilocybin in the Treatment of Alcohol Use Disorder

Clearmind Announces Notice of Proposed Stock Consolidation

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES...

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

PT358 – Dr. Rick Barnett, Psy.D – Contexts of Use: Exploring...

Delix Therapeutics Expands World-Class Team with First Head of R&D

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY